Fibrates and future PPARα agonists in the treatment of cardiovascular disease
暂无分享,去创建一个
[1] V. Athyros,et al. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. , 2002, Diabetes care.
[2] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[3] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[4] Ames,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[5] AndrewJ. S. Coats. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.
[6] R. Karas,et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. , 2007, Journal of the American College of Cardiology.
[7] Alberto Zambon,et al. Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR–&agr; Activators: Clinical and Experimental Evidence , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[8] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[9] I. Yamaguchi,et al. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. , 2004, Journal of the American College of Cardiology.
[10] B. Staels,et al. Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis , 2006, Expert opinion on emerging drugs.
[11] M. Davidson. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions , 2006, Expert opinion on drug safety.
[12] B. Rovin,et al. PPAR-α Ligands Inhibit H2O2-Mediated Activation of Transforming Growth Factor-β1 in Human Mesangial Cells , 2002 .
[13] Philippe Lefebvre,et al. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis , 2006 .
[14] T. Rabelink,et al. Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles. , 2001, Cardiovascular research.
[15] G. Werther,et al. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. , 2006, Current medicinal chemistry.
[16] A. Gotto,et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. , 1999, Circulation.
[17] D. Goff,et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.
[18] M. Quon,et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. , 2005, Diabetes care.
[19] A. Sugawara,et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha. , 2006, Diabetes.
[20] G. Watts,et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. , 2003, Diabetes.
[21] J. LeLorier,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[22] Dorne Pa. [Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced but prolonged dosage over several years (author's transl)]. , 1977 .
[23] D. Mikhailidis,et al. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study. , 2001, Metabolism: clinical and experimental.
[24] J. Achard,et al. [Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency]. , 1999, Nephrologie.
[25] A. Keech,et al. Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate , 2007 .
[26] J. Gamble,et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[27] U. Goldbourt,et al. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. , 2008, Journal of the American College of Cardiology.
[28] J. Mckenney,et al. Safety considerations with fibrate therapy. , 2007, The American journal of cardiology.
[29] S. Jackson,et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. , 2000, Circulation.
[30] G. Lewis,et al. HDL metabolism in hypertriglyceridemic states: an overview. , 1999, Clinica chimica acta; international journal of clinical chemistry.
[31] P. McBride,et al. Triglycerides and risk for coronary heart disease. , 2007, JAMA.
[32] Christopher P Cannon,et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. , 2008, Journal of the American College of Cardiology.
[33] F. Gonzalez,et al. Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules. , 2002, Journal of the American Society of Nephrology : JASN.
[34] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[35] D. Playford,et al. Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. , 2003, Atherosclerosis.
[36] H. Superko,et al. Beyond LDL cholesterol reduction. , 1996, Circulation.
[37] R. Subramanian,et al. Effects of fibrates on metabolism of statins in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[38] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[39] João Costa,et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trials , 2006, BMJ : British Medical Journal.
[40] A. Hamsten,et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients , 1996, The Lancet.
[41] Peter Libby,et al. The forgotten majority: unfinished business in cardiovascular risk reduction. , 2005, Journal of the American College of Cardiology.
[42] R. Collins,et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.
[43] M. Quon,et al. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. , 2005, Hypertension.
[44] J. Hokanson,et al. Plasma Triglyceride Level is a Risk Factor for Cardiovascular Disease Independent of High-Density Lipoprotein Cholesterol Level: A Metaanalysis of Population-Based Prospective Studies , 1996, Journal of cardiovascular risk.
[45] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.
[46] M. Quon,et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. , 2005, Journal of the American College of Cardiology.
[47] E. Schaefer,et al. Hypertriglyceridemia and cardiovascular risk reduction. , 2007, Clinical therapeutics.
[48] G. Luc,et al. Regulation of Human ApoA-I by Gemfibrozil and Fenofibrate Through Selective Peroxisome Proliferator–Activated Receptor &agr; Modulation , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[49] James W. Anderson,et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). , 2002, Archives of internal medicine.
[50] S. Pocock,et al. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes , 2006, Diabetes Care.
[51] J. Wittes,et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. , 2001, JAMA.
[52] M. Farnier,et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. , 2007, American heart journal.
[53] Sui Huang,et al. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition , 2008, Proceedings of the National Academy of Sciences.
[54] D. Mikhailidis,et al. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias : An open-label, multicenter study , 2001 .
[55] J Auwerx,et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.
[56] Lulu Chen,et al. Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1. , 2006, Vascular pharmacology.
[57] B. Rovin,et al. PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells. , 2002, Antioxidants & redox signaling.
[58] G. Luc,et al. Fenofibrate Increases Homocystinemia Through a PPAR&agr;-Mediated Mechanism , 2004 .
[59] E. Whitney,et al. Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl. , 1997, The American journal of cardiology.
[60] L. Tenkanen,et al. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. , 1995, Circulation.
[61] Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.
[62] Jeong-Hun Kim,et al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. , 2007, Experimental eye research.
[63] C. Abbott,et al. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. , 1993, The Biochemical journal.
[64] A. Kontush,et al. Antiatherogenic small, dense HDL—guardian angel of the arterial wall? , 2006, Nature Clinical Practice Cardiovascular Medicine.
[65] O. Hess,et al. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. , 1995, Journal of the American College of Cardiology.
[66] B. Staels,et al. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. , 2006, The Journal of clinical investigation.
[67] A. Keech,et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus , 2007, Diabetologia.
[68] J. Kastelein,et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. , 2005, Journal of the American College of Cardiology.
[69] Z. Varghese,et al. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Commentary , 2006 .
[70] P. Mitchell,et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.
[71] S. Grundy,et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). , 2005, The American journal of cardiology.
[72] J. O’Keefe,et al. Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer. , 2004, Mayo Clinic proceedings.
[73] L Cordain,et al. The paradoxical nature of hunter-gatherer diets: meat-based, yet non-atherogenic , 2002, European Journal of Clinical Nutrition.
[74] J. Frohlich,et al. Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus. , 2004, The American journal of cardiology.
[75] F. Violi,et al. MRC/BHF Heart Protection Study , 2002, The Lancet.
[76] E. Bruckert,et al. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.
[77] C. Vaughan,et al. MRC/BHF Heart Protection Study , 2002, The Lancet.
[78] D. Tanné,et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. , 2005, Archives of internal medicine.
[79] P. Ridker,et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.
[80] M. Nieminen,et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.
[81] J. Larosa. At the heart of the statin benefit. , 2005, Journal of the American College of Cardiology.
[82] A. Hamsten,et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. , 2000, Journal of the American College of Cardiology.
[83] Bezafibrate Infarction Prevention study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. , 2000, Circulation.
[84] G. Lip,et al. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. , 2001, The American journal of cardiology.
[85] W. März,et al. Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics , 2004, Kidney and Blood Pressure Research.
[86] B. Harrold,et al. A Double-blind Controlled Trial of Clofibrate in the Treatment of Diabetic Retinopathy , 1969, Diabetes.